Technological University Dublin

ARROW@TU Dublin
Articles

School of Food Science and Environmental
Health

2021

Influence of Molecular Weight Fractionation on the Antimicrobial
and Anticancer Properties of a Fucoidan Rich-Extract From The
Macroalgae Fucus Vesiculosus
Eduarda M. Cabral
Teagasc, Ireland

Julie Mondala
Technological University Dublin, julie.mondala@tudublin.ie

Márcia Oliveira
University of León, León, Spain

See next page for additional authors
Follow this and additional works at: https://arrow.tudublin.ie/schfsehart
Part of the Medicine and Health Sciences Commons

Recommended Citation
Eduarda M.Cabrala, E.M., Mondala, J.R.M. & Oliveira, M. (2021). Influence of Molecular Weight
Fractionation on the Antimicrobial and Anticancer Properties of a Fucoidan Rich-Extract From The
Macroalgae Fucus Vesiculosus. International Journal of Biological Macromolecules, vol. 186, pg.
994-1002. doi:10.1016/j.ijbiomac.2021.06.182.

This Article is brought to you for free and open access by
the School of Food Science and Environmental Health at
ARROW@TU Dublin. It has been accepted for inclusion in
Articles by an authorized administrator of ARROW@TU
Dublin. For more information, please contact
arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie,
gerard.connolly@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

Authors
Eduarda M. Cabral, Julie Mondala, Márcia Oliveira, Joanna Przyborska, Stephen Fitzpatrick, Dilip K. Rai,
Saravana Periaswamy Sivagnanam, Marco Garcia-Vaquero, Denis O'Shea, Michael Devereux, Brijesh K.
Tiwari, and James Curtin

This article is available at ARROW@TU Dublin: https://arrow.tudublin.ie/schfsehart/498

International Journal of Biological Macromolecules 186 (2021) 994–1002

Contents lists available at ScienceDirect

International Journal of Biological Macromolecules
journal homepage: www.elsevier.com/locate/ijbiomac

Influence of molecular weight fractionation on the antimicrobial and
anticancer properties of a fucoidan rich-extract from the macroalgae
Fucus vesiculosus
Eduarda M. Cabral a, Julie Rose Mae Mondala b, Márcia Oliveira c, Joanna Przyborska d,
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The objective of this study was to investigate the antimicrobial and anticancer properties of a fucoidan extract
and subsequent fractions isolated from the macroalgae Fucus vesiculosus. The fractions obtained (>300 kDa,
<300 kDa, <100 kDa, <50 kDa and <10 kDa) could inhibit the growth of B. subtilis, E. coli, L. innocua and
P. fluorescens when assayed at concentrations between 12,500 and 25,000 ppm. The bacterial growth was
monitored by optical density (OD) measurements (600 nm, 24 h) at 30 ◦ C or 37 ◦ C, depending upon on the strain
used. The extracted fractions were also tested for cytotoxicity against brain glioblastoma cancer cells using the
Alamar Blue assay for 24 h, 48 h and 6 days. The >300 kDa fraction presented the lowest IC50 values (0.052% 24 h; 0.032% - 6 days). The potential bioactivity of fucoidan as an antimicrobial and anticancer agent was
demonstrated in this study. Hence, the related mechanisms of action should be explored in a near future.

1. Introduction
Macro algal polysaccharides have recently attracted the attention of
the scientific community as a source of hydrocolloids [1] and other
water-soluble carbohydrates, i.e., glucans or fucoidans, for nextgeneration applications in the pharmaceutical and food industries,
such as functional food or nutraceuticals amongst others [2]. Nutra
ceuticals are molecules added to food formulations that are able to
display health benefits beyond those of basic nutrition and thus, may
play a key role in preventing certain pathological syndromes, avoiding
at the same time the secondary effects of the conventional pharmaco
logical treatments [3]. Glucans were studied for their anti-inflammatory
properties and their effects on the biochemistry and microbiology of the
human gut microbiota [4]. However, amongst all the water-soluble

polysaccharides obtained from brown macroalgae, the fucosecontaining sulphated polysaccharides or fucoidans have attracted a
huge deal of attention for their promising biological properties and
possible applications in both nutraceutical and pharmaceutical in
dustries [5]. Fucoidans are described as cell wall polysaccharides pro
duced by brown macroalgae to protect the biomass from environmental
stresses [6]. When extracted, these compounds show a wide range of
biological activities including antimicrobial [7] and antitumor [8]
properties. The exponential growth of food contamination by foodborne and spoilage microorganisms such as Listeria spp., Escherichia
coli, Pseudomonas fluorescens and Bacillus subtilis amongst others has
increased the search for natural antimicrobial agents [9,10]. Within all
the natural alternatives researched so far, the use of marine poly
saccharides like fucoidans extracted from different brown macroalgae
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has shown promising antimicrobial activities against a wide range of
pathogens and food microbes [11–13]. Fucoidans have also shown
promising anticancer activities when assayed in multiple in vitro and in
vivo model systems [14,15], and also synergistic effects with current
anticancer therapies. The related anticancer mechanism of action pre
sented by fucoidans includes the induction of cell cycle arrest and
apoptosis, together with induction of inflammation through immune
system pathways, oxidative stress and stem cell mobilization [14–16]. In
general, fucoidans are composed of a backbone of α-(1-3)-linked fucose
units or alternating α-(1-3) and α-(1-4) disaccharide units of fucose
residues with variable degrees of sulphation [17]. The chemical struc
ture and molecular weight of fucoidans can be associated with biological
factors affecting the macro algal biomass [5,17]. The extraction and
purification processes used to obtain these polymers can result in mix
tures of compounds with variable molecular weights ranging from five
to several hundred kDa [17] with variable biological properties and
difficulties to maintain the consistency of their production at industrial
level [5]. This study aims to explore the antimicrobial and anticancer
properties of a fucoidan extract from F. vesiculosus supplied by local
industry and obtained from production at industrial-scale. The extract
was fractionated through multiple molecular weight cut-off (MWCO)
membranes and the chemical, antimicrobial and anticancer properties of
each fraction were determined aiming to elucidate the most biologically
active fucoidan fractions for further applications.

2.3. Chemical analyses
All the chemical analyses were performed in triplicate.
2.3.1. Proximate composition analyses
The extract dry matter was determined by oven-drying the samples
(105 ◦ C, 16 h) and the ash content by igniting the samples in a muffle
furnace (550 ◦ C, 6 h) following the AOAC.942.05 [18]. The fat content
of the extract was determined using an NMR fat analyser (Oracle, CEM
Corporation, USA) validated according to the AOAC 2008.06 method
[19]. The protein content was determined by measuring the nitrogen
content of the samples in a LECO FP 528 instrument (Leco Instruments
UKLTD., Cheshire, UK) and applying a conversion factor 4.17 as
described for brown macroalgae by Biancarosa et al. in 2017 [20].
2.3.2. Carbohydrate analyses
2.3.2.1. Fucoidan content using high performance liquid chromatography
refractive index (HPLC-RI) detector. The fucoidan content of the samples
studied was quantified using a HPLC system (Agilent 1200 LC system,
Agilent Technologies, Santa Clara, California, USA) fitted with a
refractive index detector connected with a guard column (SUPELGUARD
H 5 cm × 4.6 mm) and a SUPELCOGEL™ C610H with 6% cross-linked
HPLC carbohydrate column with 30 cm × 7.8 mm (length × I.D.) and
9 μm of particle size (Sigma-Aldrich, Bellefonte, PA, USA). All samples
were prepared with a concentration of 2 mg/mL with the running sol
vent and filtered through 0.45 μm filters (Econo Filter, PTFE, Agilent)
and 10 μL were injected on to the column aided by an auto-sampler. The
separation was achieved using 0.1% phosphoric acid as the mobile phase
at a constant flow rate (0.5 mL/min, 20 min) at 30 ◦ C of column tem
perature. The identification of fucoidan was performed by comparison
of the retention times with those of fucoidan standard from F. vesiculosus
(≥95% purity, CAS n◦ 9072-19-9, Sigma-Aldrich, St. Louis, MO, USA)
[35]. The integration of the peaks was performed using the software
Agilent Chemstation. A standard curve was developed using different
concentrations of fucoidan (0.25–2.5 mg/mL). All the analyses were
performed in duplicate and the fucoidan content was expressed in g.

2. Material and methods
2.1. Extract generation
The Fucoidan rich-extract was obtained from Nutramara Ltd. The
raw material was Fucus vesiculosus harvested in April 2019 in Co.
Galway. The extract was prepared using a proprietary process.
2.2. Molecular weight cut-off fractionation
The fucoidan rich-extract from F. vesiculosus was re-suspended in
distilled water (5%, w/v) and the molecular weight cut-off (MWCO)
fractionation of the sample was done using an Amicon® Stirred Cell
(Millipore Corporation, MA, USA). The optimal concentration of the
samples was achieved by ultra-filtrating the samples through
polyethersulfone membranes Biomax™ (Merck Millipore, Darmstadt,
Germany) using compressed air (5 bar) and magnetic stirring. The
scheme to perform a sequential MWCO using 300 kDa, 100 kDa, 50 kDa
and 10 kDa membranes is summarised in Fig. 1. All the fractions were
freeze-dried (FD80 model 119, Cuddon Engineering, Blenheim, New
Zealand), vacuum sealed and stored at − 20 ◦ C for further chemical,
antimicrobial and anticancer analyses.

2.3.2.2. Total glucan measurement. Total glucans were determined
using the kit K-YBGL (Megazyme Ltd., Bray, Ireland). Briefly, 100 mg of
yeast β-glucan (positive control) and unknown samples were hydrolysed
using a 1 M HCl solution in a water bath (100 ◦ C, 2 h). Samples were
neutralised with 2 M KOH, adjusted to 100 mL with sodium acetate
buffer (pH 5.0) and centrifuged (1000 g, 10 min). 100 μL of positive
control, blanks (sodium acetate buffer, pH 5.0), D-glucose standards (1
mg/mL) and unknown samples were treated using an enzymatic solution
containing exo-1,3-β-glucanase (20 units, U/mL) and β-glucosidase (4

Fig. 1. Scheme summarizing the main equipment and processing steps to perform MWCO fractionation of the fucoidan extract.
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U/mL), followed by the addition of glucose-oxidase-peroxidase
(GOPOD) reagent. The absorbance of all the samples was read at 510
nm using a spectrophotometer (Epoch, BioTek, Winooski, VT, USA).

culture collection of Prof. Michael Carty (Trinity College, Dublin,
Ireland). Cells were cultured in Dulbecco’s Modified Eagle’s Mediumhigh glucose (Merck, Germany) supplemented with 10% foetal bovine
serum (Merck) and 1% penicillin-streptomycin solution (Merck, Ger
many) in TC flask T75, standard for adherent cells (Sarstedt, Ireland).
The cultures were maintained in a humidified incubator containing 5%
CO2 at 37 ◦ C. Culture medium was changed every 2–3 days until 80%
confluence was reached. Cells were routinely sub-cultured using 0.25%
trypsin-EDTA solution (Merck, Germany). Cells were seeded at a density
of 1 × 104 cells/well (24 and 48 h treatment) or 2.5 × 103 cells/well (6
days treatment) (100 μL culture medium per well), in triplicate in 96well plates (Greiner Bio-One, United Kingdom). Plates were incubated
overnight at 37 ◦ C with 5% CO2 to allow proper adherence. Existing
media was removed from each well and cells were then treated with
10% of the 10% (w/v) of each of the different fucoidan fractions and
serially diluted from 1 to 0.0078%; 20% dimethyl sulfoxide (DMSO) was
used as a positive control and media was used as negative control.

2.4. Antimicrobial properties
2.4.1. Microorganisms and culture conditions
The antimicrobial activity of the studied macroalgae fractions was
tested using the following strains of bacteria: Listeria innocua NCTC
11288, Escherichia coli K12 DH5α, Pseudomonas fluorescens DSM 50090
and Bacillus subtilis. All strains were obtained from ceramic beads in
glycerol at − 80 ◦ C from the collection of Teagasc Food Research Centre,
Ashtown, Dublin, Ireland. Before each assay, a bead of each strain was
streaked on Tryptone Soy Agar (TSA, Oxoid, U.K) and incubated for 18 h
at either 37 ◦ C in the case of L. innocua and E. coli or 30 ◦ C for
P. fluorescens and B. subtilis. A single colony was removed from each
plate and inoculated into tubes containing Tryptone Soy Broth (TSB,
Oxoid, UK) and incubated for 22 h at the appropriate temperature of
each bacterial strain (30 or 37 ◦ C). Subsequently, the cells were har
vested by centrifugation at 8000 rpm (6 min, 4 ◦ C) and re-suspended in
Maximum Recovery Diluent (MRD, Oxoid, UK). The initial concentra
tion of each strain was confirmed by serial dilutions plating on TSA and
incubated for 18–20 h at either 30 or 37 ◦ C.

2.5.2. Cell viability assay
The Alamar Blue assay encompasses a fluorometric/colorimetric
growth indicator based on the detection of metabolic activity. The sys
tem incorporates an oxidation-reduction indicator that both fluoresces
and changes colour in response to chemical oxidation of growth medium
as a result of cell death. A decrease in cell viability results in a colour
change from pink (reduced, fluorescent) to blue (oxidised, nonfluorescent). The Alamar Blue assay (Invitrogen, Ireland) was used to
measure the effects of macroalgal fractions extracted against U-251MG
cells. After 24 h, 48 h and 6 days of incubation at 37 ◦ C in 5% CO2, the
cells were rinsed once with phosphate buffered saline (Merck, Ger
many), and then incubated for 2.5 h at 37 ◦ C with 10% Alamar blue and
90% DMEM-high glucose solution. The cell viability was measured by
fluorescence (excitation, 530 nm; emission, 590 nm) using a Vari
oskan™ LUX multimode microplate reader (Thermo Scientific, USA).

2.4.2. Minimum inhibitory concentration (MIC) assay
The MIC’s of the macroalgal fractions were estimated according to
the method developed by Smyth et al. [31]. Each fraction was resuspended in sterile water (10%, w/v) and this initial solution was
further diluted in sterile water in order to obtain in the well each of the
following concentrations: 5%, 2.5%, 1.25%, 0.625%, 0.3125%, 0.156%
and 0.078%. The inoculum of the target microorganism was diluted
appropriately in MRD to achieve a concentration in the well of log 6.0 ±
0.5 CFU/mL. 100 μL of each seaweed fraction concentration was mixed
with 80 μL of TSB and 20 μL of bacteria in each well of the 96 well flatbottom microplate. The microplates were covered, incubated during 24
h and then checked for growth using the iodonitrotetrazolium chloride
(INT) method as an appropriate indicator of microbial growth [32]. The
MIC of each seaweed fraction against the target microorganism was
determined as the lowest concentration at which no pink colour
appeared. Since some fraction concentrations presented an ambiguous
pink colour, the test was complemented with the seeding of a 10 μL loop
in TSA to confirm the absence of growth. This assay was repeated twice
for each bacterial strain to ensure reproducibility.

2.6. Statistical analyses
For the antimicrobial properties of all the fractions, the primary
growth parameters were obtained by plotting and fitting OD600 against
incubation time to the modified Gompertz model using the DMFit excel
based tool [33]. The maximum specific growth rate (μmax), lag phase (λ,
h) were determined using Eq. (1).
ODt = OD0 +

2.4.3. Bacterial growth curves and model fitting
The effect of the macroalgal fractions on L. innocua, E. coli,
P. fluorescens and B. subtilis growth was monitored by optical density
(OD) measurements at 600 nm at a regular interval of 30 min using 96
well plates in a temperature-controlled microplate reader spectropho
tometer (Epoch 2, BIOTEK, USA), during 24 h at 30 ◦ C or 37 ◦ C
depending upon on the strain used. The concentrations used for each
macroalgal fraction were based on the MIC’s assay results for each
microorganism. Each well was inoculated in triplicate with 100 μL of
each macroalgal fraction, 80 μL of TSB and 20 μL of bacterial suspension
with concentration in the well of log 4.0 ± 0.5 CFU/mL. A control of
bacterial growth was performed with TSB and another control of bac
terial growth inhibition was performed with gentamicin (initial con
centration of 500 mg/L for Gram-negative) and vancomycin (initial
concentration of 500 mg/L for Gram-positive). The growth curves were
repeated in triplicate for each bacterial strain to ensure reproducibility.

[ODmax − OD0 ]
[1 + e(− B(t− M) ]

(1)

where, OD0 and ODmax are the initial and maximum optical density [-];
ODt is the optical density at incubation time (h); B is the maximum
relative growth (h− 1) at t = M and M is time (h) at which the absolute
growth rate was maximum. Maximum relative growth (B, h− 1) and M
can be used to calculate the SGR and lag phase of the growth curve. The
SGR and lag phase for the modified Gompertz model can be calculated
by using Eq. (2) [34].
Specific growth rate (μmax ) =

[ODmax − OD0 ]
×B
e

(2)

Lag phase (λ) = M − B1 (Eq. (2)); where “e” is the base for natural
logarithms.
Regarding the anticancer properties, all assays were performed in
triplicate, independently of each other with a minimum of three repli
cates per experiment. Data shown is pooled and presented as mean ±
SEM (n = total number of replicates) unless stated otherwise. Curve
fitting and statistical analysis was performed using Prism 9, GraphPad
Software, Inc. (USA). Unless otherwise indicated, significant differences
were considered with a *P value <0.05.

2.5. Anticancer properties
2.5.1. Cell culture
The human brain glioblastoma cancer cell line (U-251 MG (formerly
known as U-373 MG) (ECACC 09063001)) cells were obtained from the
996
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3. Results and discussion

Table 2
Chemical composition of the fucoidan extract and subsequent molecular weight
fractions generated using MWCO techniques.

3.1. Chemical composition of the fucoidan extract and subsequent
fractions
The proximate composition (moisture, ash, crude lipids, protein and
total glucans) of the fucoidan extract is summarised in Table 1. In gen
eral, the extract revealed a high amount of ash, which can be related
with the high content of minerals in macroalgae. The levels of total
glucans, lipids and proteins were all at concentrations of <3% in this
extract.
The chemical composition of each fraction collected at each molec
ular weight (>300 kDa, <300 kDa, <100 kDa, <50 kDa and <10 kDa) is
summarised in Table 2. Overall, the majority of the water-soluble
compounds were retained in the fraction >300 kDa, particularly in
the case of fucoidan, with 82.23 ± 3.03% retained in this high molecular
fraction. Similarly to other studies evaluating high and low molecular
weight fucoidans obtained via MW fractionation and ultrafiltration, the
chemical composition and structure elucidation of the most promising
fractions will deserve further study and elucidation [21]. In our study,
the fractions B to E (Table 2) showed lower fucoidan content, which can
be due to the presence of low molecular weight fucoidan passing
through the membrane system. In addition, the retention time of these
particular samples came after 9 min (Fig. not shown) which can be
related with low molecular weight fucoidans. The fucoidan content (g)
(Table 2) was determined using HPLC-RI [35], and the resulting chro
matograms are presented in Fig. 2b–d respectively. The chromatograms
of the standard, whole fraction and fraction A (>300 kDa) showed that
the retention time of fucoidan was around 8.7 min respectively. The
standard curve was performed using different concentration of fucoidan
(0.25–2.5 mg/mL), with a linearity of R2 = 0.9964 (Fig. 2a). It was
observed that both the standard and fraction A (>300 kDa) showed one
sharp peak, while the chromatogram of the whole fraction sample
consisted of an unresolved adjacent peak. This indicates the presence of
two components co-eluting together in the crude sample, suggesting that
the crude fucoidan isolated from F. vesiculosus is highly complex in
composition confirming the presence of other components.
In the case of the remaining water-soluble compounds presented in
the fucoidan extract from brown macroalgae, the subsequent fractions
obtained from the fucoidan extract were also analysed. The accumula
tion of both protein and total glucans followed in general a similar
pattern to the fucoidan content of the extract, although in lower con
centrations. Total glucans and proteins were retained mainly in the
higher molecular weight fraction. However, the overall concentration of
these compounds in the extracts was very low and thus, the levels of
total glucans represent 1.61 ± 0.15 g per 100 g of this fraction. The
protein content had a similar behaviour to that of total glucans and was
present in low concentration in all the fractions generated from this
fucoidan extract.
Fucoidan content (g) is expressed in absolute terms as g of com
pounds per dried weight of fucoidan extract or fractions (A–E). The
amount of other minor water-soluble compounds of the extract (protein
and total glucans) were also analysed in each fraction. Numbers in
brackets indicate the % of compounds retained in each fraction with

Fucoidan rich-extract (average ± SEM)

Moisture (%)
Ash (%)
Crude lipids (%)
Protein (%)
Total glucans (%)

4.19 ± 0.09
17.58 ± 0.07
2.57 ± 0.12
2.20 ± 0.01
2.32 ± 0.18

Protein (g)

Total glucans (g)

Fucoidan content
(g)

Whole fraction

3.30 ± 0.01
(100%)
1.72 ± 0.01
(52.05 ± 0.28%)
1.21 ± 0.03
(36.52 ± 0.78%)
0.56 ± 0.00
(17.08 ± 0.10%)
0.30 ± 0.01 (9.06
± 0.26%)
0.15 ± 0.00 (4.52
± 0.03%)

2.32 ± 0.18
(100%)
1.61 ± 0.15
(69.36 ± 5.72%)
1.00 ± 0.03
(43.15 ± 1.49%)
0.54 ± 0.03
(23.36 ± 1.38%)
0.20 ± 0.01 (8.79
± 0.23%)
0.12 ± 0.01 (5.36
± 0.49%)

63.26 ± 0.62
(100%)
50.88 ± 1.87
(80.43 ± 2.96%)
6.55 ± 0.09 (10.35
± 0.14%)
2.85 ± 0.04 (4.50 ±
0.06%)
1.08 ± 0.08 (1.70 ±
0.13%)
0.94 ± 0.03 (1.48 ±
0.05%)

Fraction A
(>300 kDa)
Fraction B
(<300 kDa)
Fraction C
(<100 kDa)
Fraction D
(<50 kDa)
Fraction E
(<10 kDa)

respect to the original fucoidan extract filtrated.
3.2. Antimicrobial properties
Fucoidan alongside with laminarin, phlorotannins, alginic acids, etc.
have been attracting huge attention amongst the research community
due to the multiple bioactivities presented, in particular antimicrobial
properties [22]. In our study, the fractions extracted (>300 kDa, <300
kDa, <100 kDa, <50 kDa and <10 kDa) from the fucoidan extract were
tested for antimicrobial properties against two Gram-positive (B. subtilis
and L. innocua) and two Gram-negative (E. coli and P. fluorescens) bac
terial strains. Overall, as seen in Fig. 3 all the fractions generated from
the fucoidan rich-extract were able to inhibit bacterial growth of both
Gram-positive and negative bacteria when assayed at high concentra
tions (12,500–25,000 ppm), while concentrations of 500 ppm allowed
the growth of all bacteria. The growth rate of these microorganisms was
drastically reduced with the increase of concentration (Fig. 3) in each
and every fraction studied (data not shown). In the case of B. subtilis and
P. fluorescens, the results of the extract at high concentration may be
influenced by the effect of other minor soluble compounds present in the
extract. At low concentration, the fucoidan content of this extract is the
main compound present in these fractions, while the contents of other
soluble compounds are minimum. However, at increased concentrations
of the extract, the amount of other minor compounds of the extract can
considerably increase, thus, influencing bacterial growth at subinhibitory concentrations. The increase of biomass observed with
P. fluorescens can be explained by stress induced through the exposition
to the tested substances at sub-inhibitory concentrations, which maybe
leads to an extra production of exopolysaccharides (EPS) by the bacterial
cell as observed with P. aeruginosa exposed to the natural compound,
casbane diterpene [23]. Moreover, similarly to the results reported for
these fucoidan fractions, variable results have been reported in recent
scientific literature examining the antimicrobial properties of fucoidan.
Liu et al. in 2017 [12] reported no antibacterial activity of fucoidan
extracted from Laminaria japonica against E. coli and S. aureus even at
high concentrations (10 mg/mL). The authors reported that the depo
lymerisation of the molecules following high-pressure methods and
thus, the reduction of the molecular weight of the original molecules
was key to increase the antibacterial properties of fucoidans through the
destruction of cytomembranes and targeting bacterial membrane pro
teins [12]. Jun et al. in 2018 [11] studied the antimicrobial properties of
fucoidan extracted from multiple macroalgae and obtained the highest
antibacterial activities against multiple bacteria in those compounds
from F. vesiculosus with minimum inhibitory concentrations ranging
from 125 to 1000 μg/mL. Moreover, the slight differences observed
between the fucoidan fractions in this study could also be attributed to
the presence of phenolic compounds, such as phlorotannins, and other
minor algal components with known antimicrobial properties [24–26].
The growth of bacterial cells in all the fractions generated in this study at

Table 1
Proximate composition of the fucoidan extract.
Parametersa

Fraction

a
The units of all the parameters are expressed of % or g per 100 g of dried
extract.
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Fig. 2. a) Standard curve of fucoidan; b) HPLC-RI chromatogram of fucoidan standard (2 mg/mL); c) whole fraction and d) fraction A (>300 kDa).

Fig. 3. Effect of concentration on microbial ( ) growth or ( ) inactivation. (For interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)

500 ppm was monitored over a 24 h period using optical density mea
surements at 600 nm. Fig. 4 shows the plotted average optical density at
each incubation time (30 min) for L. innocua, B. subtilis, E. coli and
P. fluorescens subjected to incubation with a fixed concentration of the
different fucoidan fractions (>300 kDa, <300 kDa, <100 kDa, <50 kDa,
<10 kDa) against control (distilled water). The initial OD 600 nm was in
a range of 0.001 to 0.038 OD units irrespective of the treatment. As can
be seen from Fig. 4, the slope of the exponential phase of treated and
control bacterial cells were parallel, indicating that the growth

behaviour was relatively similar. Significant increase in lag time was
observed only in the case of L. innocua when treated with >300 kDa
samples compared with the other fractions. The growth parameters
obtained by plotting OD 600 nm versus incubation time (h) following
the Gompertz model are summarised in Table 3. This model was
employed to obtain key growth parameters on the effect of the fucoidan
fractions on the behaviour of Gram-positive and negative bacteria
including their specific growth rate (μmax, OD unit/h) and lag phase (λ,
h). The predicted growth model was tested for the accuracy of model fit
998
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Fig. 4. Growth curves of B. subtilis (a), E. coli (b), L. innocua (c) and P. fluorescens (d) over a 24 h incubation period at 30 or 37 ◦ C plotted using Gompertz model fitting subjected to 500 ppm of different fucoidanrich fractions.

by using R2 and RMSE values (Table 4). The specific growth rates (μmax,
OD units/h) and lag phases (λ, h) obtained from Gompertz model for the
different bacteria did not differ between the different fucoidan fractions
tested, with exception of L. innocua. For that particular microorganism,
significant statistical differences (P < 0.05) were observed, with the
fraction >300 kDa presenting the highest λ value, a fact that can be
attributed to a higher susceptibility of this particular microorganism to
fucoidans, glucans and other antimicrobial bioactives present at high
concentrations in the >300 kDa fraction (Table 2). Despite the lack of
statistical differences in the λ amongst most of the microorganisms
tested, a relevant result of the present study is the fact that just after
approximately 10 h or above (see Fig. 4) the microorganisms started
showing some growth at their optimal incubation temperatures (either
30 or 37 ◦ C) amongst all the fractions tested. Many foodborne bacteria
form biofilms on the surfaces of food, which can cause food spoilage and
disease infections. However, with the supplementation of antimicro
bials, as is the case of fucoidans from seaweed, it is expected that some of
these issues can be delayed or resolved. The promising results open up
new possibilities for research on the use of fucoidan fractions as natural
bacteriostatic and bactericidal ingredients for multiple applications,
including food preservatives. Studies focusing on this particular use of
fucoidan applied to food are scarce in the scientific literature. PovedaCastillo et al. in 2018 [7] appreciated both a bacteriostatic and bacte
ricidal effect of fucoidan against Listeria monocytogenes and Salmonella
typhimurium in vitro, validating these results by adding these compounds
to pasteurized apple beverage to be commercialized under refrigeration.
3.3. Anticancer properties
The anticancer properties of fucoidan have been extensively studied
since the 80s. Since then, different studies have shown that these mol
ecules can suppress cancer cells proliferation, induce apoptosis, suppress
angiogenesis, etc., both in vitro and in vivo studies [15]. Previous re
ports have demonstrated that fucoidan molecular weight have been
considered one of the main factors that affect in vitro anticancer activ
ities, where low molecular weight has been reported to have higher
cytotoxicity due to its ability to increase the solubility and penetration
into the cell with reduced toxic effect to normal cells. In our study, the
fractions extracted (>300 kDa, <300 kDa, <100 kDa, <50 kDa and <10
kDa) were tested for cytotoxic activities using a glioblastoma multiforme
U-251MG cancer cell line with the Alamar Blue assay over an incubation
period of 24 h, 48 h and 6 days (see Fig. 5). The IC50 values obtained are
summarised in Table 5. Overall, the most promising fraction required to
inhibit 50% of cell growth is the >300 kDa (Fraction A). This particular
fraction presented the lowest IC50 value when compared with the other
four fractions studied amongst the incubation periods, with values
ranging from 0.074% (48 h treatment) to 0.032% (6 days treatment). It
can be observed that the IC50 of 48 h is higher than the 24 h treatment,
which could possibly be because the proliferation of some cells con
tinues in the short-term when incubated with moderately toxic con
centrations. That would lead to a perceived increase in viability as these
cells divide, but they too can succumb to slower cytotoxicity kinetic.
This pattern was also seen with other cytotoxic agents, and we tend to
select 6 days as endpoint with the cell line. The Hill slope also agrees
with this, as seen in Fig. 5, there is a much steeper Hill slope in the
cytotoxicity data for 48 h and 6 days, compared with 24 h, indicating
that lower concentrations lead to a population of survivor cells that
continues proliferating at this early time point. These results can be
attributed to a higher susceptibility of the cancer cells studied to
fucoidans, glucans and other anticancer bioactives present at higher
concentrations in the >300 kDa fraction (Table 2). Treatments for brain
cancer are hindered by the tight junction of the blood brain barrier
(BBB), and fucoidans are known to bind to P-selectin which is found on
the cell surface of endothelial cells of BBB [27]. P-selectin is also known
to be involved in rolling and arresting of leukocytes. Thus, binding of
fucoidan to P-selectin can inhibit entry of leukocytes into the brain,
999
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Table 3
Effect of various fractions on microbial specific growth parameter (μmax, h− 1) and lag phase (λ, h).
Fractions

B. subtilis

E. coli

− 1

μmax (h )
Fraction A (>300 kDa)
Fraction B (<300 kDa)
Fraction C (<100 kDa)
Fraction D (<50 kDa)
Fraction E (<10 kDa)
MSD

λ (h)
a

0.042 ± 0.002
0.041 ± 0.013a
0.040 ± 0.001a
0.036 ± 0.009a
0.051 ± 0.013a
0.0436

L. innocua
− 1

μmax (h )
a

11.424 ± 0.821
9.442 ± 1.1097a
9.629 ± 0.369a
8.443 ± 1.844a
9.507 ± 0.822a
4.854

λ (h)
a

0.062 ± 0.010
0.056 ± 0.002 a
0.051 ± 0.008a
0.065 ± 0.008a
0.071 ± 0.014a
0.0376

P. fluorescens

− 1

μmax (h )
a

9.044 ± 0.596
9.581 ± 0.329a
10.038 ± 0.142a
9.688 ± 0.114a
9.230 ± 0.419a
1.700

λ (h)
a

0.071 ± 0.005
0.127 ± 0.002a
0.104 ± 0.010a
0.091 ± 0.005a
0.113 ± 0.045a
0.101

a

19.97 ± 0.697
4.49 ± 0.044c
13.86 ± 0.740b
14.43 ± 0.462b
13.84 ± 0.002a
2.442

μmax (h− 1)

λ (h)

0.153 ± 0.005b
0.19 ± 0.001a
0.17 ± 0.009ab
0.18 ± 0.001b
0.18 ± 0.006b
0.026

15.56 ± 0.103a
15.81 ± 0.102a
18.73 ± 0.836a
17.74 ± 1.508a
16.86 ± 0.282a
3.722

Different letters in the table indicate statistical differences (P < 0.05) in the μmax and λ between the different treatments with the different fucoidan fractions.
Table 4
Statistical model parameters for Gompertz model fitted to the growth curves.
Fractions

B. subtilis

Fraction A (>300 kDa)
Fraction B (<300 kDa)
Fraction C (<100 kDa)
Fraction D (<50 kDa)
Fraction E (<10 kDa)

E. coli

L. innocua

P. fluorescens

RMSE

R2

RMSE

R2

RMSE

R2

RMSE

R2

0.008
0.023
0.028
0.011
0.012

0.759
0.966
0.948
0.915
0.882

0.007
0.003
0.003
0.005
0.006

0.996
0.997
0.999
0.999
0.996

0.010
0.013
0.012
0.010
0.142

0.994
0.958
0.989
0.988
0.994

0.025
0.013
0.011
0.018
0.020

0.996
0.998
0.995
0.996
0.998

Fig. 5. (A) 24 h (B) 48 h and (C) 6 days treatment of the different fractions in U-251MG cells. Cell viability is plotted against the Log10 exponent concentration (% w/
v). Data shown was normalised to the untreated control and are shown as mean ± S.E.M. Statistical analysis were carried out using non-linear regression analysis and
Two-way ANOVA (*P < 0.05) (n = 3).
Table 5
Summary of IC50 in percentage of fractions extracted %, (w/v; g/ml) from fucoidan rich-extract obtained at 24 h, 48 h and 6 days treatment in U-251MG cells.
Fraction
Fraction A (>300 kDa)
Fraction B (<300 kDa)
Fraction C (<100 kDa)
Fraction D (<50 kDa)
Fraction E (<10 kDa)

24 h

48 h

6 days

Statistical difference

IC50 (%)

IC50 range (%)

IC50 (%)

IC50 range (%)

IC50 (%)

IC50 range (%)

0.05203
0.09648
0.1206
0.1599
0.2247

0.04188 to 0.06423
0.07908 to 0.1165
0.09963 to 0.1453
0.1283 to 0.1973
0.1985 to 0.2536

0.08236
0.1532
0.1686
0.2628
0.2730

0.07378 to 0.09163
0.1432 to 0.1642
0.1531 to 0.1856
0.2404 to 0.2850
0.2601 to 0.2877

0.03160
0.07983
0.1375
0.1761
0.2093

0.02838 to 0.03500
0.07136 to 0.08887
0.1198 to 0.1528
0.1546 to 0.1991
0.1945 to 0.2249

1000

P
P
P
P
P

<
<
<
<
<

0.05
0.05
0.05
0.05
0.05
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reducing inflammatory response [28]. Fucoidans have also been pro
posed to be absorbed by the intestine through SGLT1 and GLUT2
transport system, which can also be a possible mechanism to deliver
drugs through BBB [29]. Our study presented promising results in the
treatment of GBM with fucoidan rich fractions and could warrant further
studies using in vivo models. Yang et al. [30] reported that fucoidan
from Undaria pinnatifida with a MW of 2200 kDa showed improved
anticancer activity (71.3%) compared with the native fucoidans
(37.6%), and the authors also found that fucoidan with an MW of 490
kDa increased the anticancer activity (75.9%) in human lung cancer cell
line, A549. From the fucoidan results obtained in our study, it is un
derstandable that the fraction >300 kDa presented the highest content
of fucoidan and better anticancer results. One the other hand, the lowest
fractions with lower fucoidan content (from HPLC-RI results) still pre
sent promising results, which can be due to the presence of low mo
lecular weight fucoidan.
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